Company

Advanced Biodesign is driven by the ambition to treat all patients facing chemotherapy-resistant cancers with elevated levels of ALDH1.

Since its inception in 2010, this French biotechnology company has :

1/ confirmed the pivotal role of ALDH1 enzymes in the metabolism of cancer cells and immunomodulation.

2/ developed a pipeline of several ALDH1 inhibitors with the potential to be a game changer in the patient care.

3/ entered clinical trial in early 2023 with its lead ABD 3001 targeting acute myeloid leukemia (AML). Initial results suggest a good safety profile. The 2nd Lead ABD 0171 is developed in solid tumors and has a potentiated effect in combination with anti-PD1.

4/ developed a predictive and prognostic test called ALDESCREEN® to identify and stratify patients.

 

 

 

 

Corporate video

 

 

 

Investors

Advanced BioDesign’s program is supported by Xerys funds.

The financing provided by Xerys funds is always associated with a strong expertise in the field of company development. This expertise manifests itself by following up the company evolution, listening attentively to the managing team and helping to define the strategic plan.